[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AP2015008624A0 - Methods of treating cardiovascular indications - Google Patents

Methods of treating cardiovascular indications

Info

Publication number
AP2015008624A0
AP2015008624A0 AP2015008624A AP2015008624A AP2015008624A0 AP 2015008624 A0 AP2015008624 A0 AP 2015008624A0 AP 2015008624 A AP2015008624 A AP 2015008624A AP 2015008624 A AP2015008624 A AP 2015008624A AP 2015008624 A0 AP2015008624 A0 AP 2015008624A0
Authority
AP
ARIPO
Prior art keywords
methods
treating cardiovascular
cardiovascular indications
indications
treating
Prior art date
Application number
AP2015008624A
Other languages
English (en)
Inventor
Johannes Holzmeister
Original Assignee
Cardiorentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ltd filed Critical Cardiorentis Ltd
Publication of AP2015008624A0 publication Critical patent/AP2015008624A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
AP2015008624A 2013-01-25 2014-01-24 Methods of treating cardiovascular indications AP2015008624A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25
PCT/IB2014/000253 WO2014115033A2 (en) 2013-01-25 2014-01-24 Methods of treating cardiovascular indications

Publications (1)

Publication Number Publication Date
AP2015008624A0 true AP2015008624A0 (en) 2015-07-31

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008624A AP2015008624A0 (en) 2013-01-25 2014-01-24 Methods of treating cardiovascular indications

Country Status (19)

Country Link
US (2) US20140213520A1 (es)
EP (1) EP2948165A2 (es)
JP (1) JP2016505065A (es)
KR (1) KR20150108903A (es)
CN (1) CN105025918A (es)
AP (1) AP2015008624A0 (es)
AU (1) AU2014208851B2 (es)
BR (1) BR112015017432A2 (es)
CA (1) CA2898571A1 (es)
DO (1) DOP2015000175A (es)
EA (1) EA201500765A1 (es)
IL (1) IL239909A0 (es)
MX (1) MX2015009606A (es)
NZ (1) NZ710246A (es)
PH (1) PH12015501559A1 (es)
SG (1) SG11201505492XA (es)
TN (1) TN2015000315A1 (es)
TW (1) TW201442722A (es)
WO (1) WO2014115033A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
JPH10500969A (ja) 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CA2425712C (en) * 2000-10-04 2017-06-06 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
EP2510942B1 (en) * 2005-04-07 2015-09-02 Cardiorentis AG Use of natriuretic peptide for treating heart failure
US8293711B2 (en) * 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Ｓｉｒｓ患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
RU2636738C2 (ru) * 2009-09-25 2017-11-28 Шайр Орфан Терапис ГмбХ Новые агонисты npr-b
WO2011038066A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
US20130197188A1 (en) * 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
CN103079546A (zh) * 2010-08-20 2013-05-01 天蓝制药公司 治疗性肽-聚合物缀合物、粒子、组合物以及相关方法

Also Published As

Publication number Publication date
JP2016505065A (ja) 2016-02-18
AU2014208851B2 (en) 2016-12-22
US20140213519A1 (en) 2014-07-31
WO2014115033A2 (en) 2014-07-31
US20140213520A1 (en) 2014-07-31
BR112015017432A2 (pt) 2017-07-11
CA2898571A1 (en) 2014-07-31
WO2014115033A3 (en) 2015-02-26
NZ710246A (en) 2016-11-25
KR20150108903A (ko) 2015-09-30
MX2015009606A (es) 2016-04-26
AU2014208851A1 (en) 2015-08-06
DOP2015000175A (es) 2015-11-15
IL239909A0 (en) 2015-08-31
PH12015501559A1 (en) 2015-09-21
TW201442722A (zh) 2014-11-16
CN105025918A (zh) 2015-11-04
SG11201505492XA (en) 2015-08-28
TN2015000315A1 (en) 2017-01-03
EP2948165A2 (en) 2015-12-02
EA201500765A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
HK1217908A1 (zh) 治療膽管癌的方法
HK1218506A1 (zh) 治療黑素瘤的方法
HK1219236A1 (zh) 猝倒的治療
GB201401248D0 (en) Method of manufacture
EP2968273A4 (en) METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
EP3632467C0 (en) INHIBITORS OF COMPLEMENT FACTOR H
HK1213817A1 (zh) 治療癌症的方法
HK1215164A1 (zh) 處理方法
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
PL3071969T3 (pl) Sposób analizy
GB201319875D0 (en) Method of measuring isotape ratio
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
HK1219513A1 (zh) 治療癌症的方法
IL239909A0 (en) Methods for treating cardiovascular signs
GB201305231D0 (en) Method of Manufacture
IL241096B (en) Treatment methods
EP2961401A4 (en) METHOD FOR TREATING OTOTOXICITY
EP2976315A4 (en) PROCESS FOR THE PREPARATION OF C5-DI OLEFINES
HK1220133A1 (zh) 改善微血管完整性的方法
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201311291D0 (en) Method of manufacture
GB201301262D0 (en) Method of manufacture
GB201320835D0 (en) HIF inhibitors